We describe a phage display methodology for engineering synthetic antigen binders (sABs) that recognize either the apo or the ligand-bound conformation of maltose-binding protein (MBP). sABs that preferentially recognize the maltose-bound form of MBP act as positive allosteric effectors by substantially increasing the affinity for maltose. A crystal structure of a sAB bound to the closed form of MBP reveals the basis for this allosteric effect. We show that sABs that recognize the bound form of MBP can rescue the function of a binding-deficient mutant by restoring its natural affinity for maltose. Furthermore, the sABs can enhance maltose binding in vivo, as they provide a growth advantage to bacteria under low-maltose conditions. The results demonstrate that structure-specific sABs can be engineered to dynamically control ligand-binding affinities by modulating the transition between different conformations.
a r t i c l e s Many biological processes are regulated through the interactions of proteins with small molecules or other proteins. In many cases, these interactions induce conformational changes that directly modulate activities or provide new binding sites that facilitate building higherorder organizations. Thus, the ability to engineer systems that can precisely control these processes could have extensive applications in biomedical research and biotechnology. Both rational and combinatorial approaches to modulating protein-ligand interactions have relied mainly on introducing mutations within the protein of interest at residues that directly involve the ligand-binding site [1] [2] [3] . An alternative strategy to modulating protein-ligand interactions is the use of allosteric effectors. Whereas mutations permanently change the affinity for the ligand, allostery can 'dial in' a range of affinities on the basis of the concentration of the allosteric effector in a controlled fashion. Many naturally occurring allosteric effectors share a common feature, namely the ability to bind preferentially to one form or conformation of the protein 4, 5 . Effectors that favor the ligand-bound form of a protein enhance binding and act as positive allosteric effectors, whereas those that favor the apo form of the protein act as negative allosteric effectors.
Monoclonal antibodies can sometimes function as enhancers or inhibitors of ligand binding 6, 7 . However, producing a panel of monoclonal antibodies to carry out a specified function is not a trivial undertaking because there is little control over the conformational states in an animal's bloodstream. Consequently-, finding a monoclonal antibody that can induce the desired function or binds to an intended epitope is not a matter of design but an expensive exercise in screening many monoclonal antibodies for the desired function.
To explore the potential of allosteric control of molecular processes, we sought to develop a general strategy to rationally engineer reagents that can dynamically modulate the binding affinity of proteins for their ligands. As a model system, we used MBP, a member of the bacterial periplasmic binding protein superfamily 8 . MBP is the soluble component of the maltodextrin transport system and resides in the periplasm of Gram-negative bacteria, where it shuttles its ligandsmaltose, maltotriose and maltotetraose-to the membrane-bound transporter complex 9, 10 . The ligand-binding site of MBP is positioned between two domains separated by a hinge region 11 . Without ligand, MBP is present almost exclusively in an open (ligand-free) conformation. Upon ligand binding, a large conformational change takes place via a hinge-bending motion of ~35° as MBP adopts a closed (ligandbound) conformation 12, 13 .
In this study, we engineered allosteric effectors based on a novel class of antibody-like affinity reagents, sABs [14] [15] [16] . We generated sABs using a phage display methodology in which a library of a humanized antibody Fab fragment was displayed on the surface of the M13 bacteriophage 17 . In contrast to monoclonal antibodies, sABs are generated in vitro, allowing control over the conformational state of the target protein. The phage display strategy takes advantage of the structural differences between the apo and ligand-bound forms of MBP 12 to generate sABs that preferentially bind either form. We carried out these selections with or without maltose to generate sABs that bind to the open or closed form of MBP, respectively. We also investigated the ability of the sABs to influence maltose binding in vitro and in vivo. We determined the crystal structure of a maltose-bound MBP in complex with one sAB, revealing the mechanism of the allosteric effect and confirming the selective conformational trapping capability of the sAB. Our results demonstrate the ability to use sAB-based affinity modulators to dynamically control (enhance or diminish) ligand binding without introducing mutations within the binding protein itself.
a r t i c l e s
The data also suggest that simple in vitro selection conditions for sAB generation can translate to in vivo function.
RESULTS

Phage display and selection strategy
To generate sABs for MBP, we used a synthetic library built on a single-antibody fragment (Fab) fused to the minor coat protein pIII of the M13 bacteriophage. The framework maximizes the number of randomized positions by introducing limited diversity into the three heavy-chain complementarity-determining regions (CDR-H1, CDR-H2 and CDR-H3) and one light-chain CDR (CDR-L3) 17 . The library (kindly provided by A. Koide, University of Chicago) overrepresents tyrosine, serine, glycine, tryptophan and phenylalanine side chains (tyrosine, 30%; serine, 15%; glycine, 10%; tryptophan, 5%; phenylalanine, 5%) at solvent-accessible positions responsible for antigen recognition. The library also includes all other amino acids at a lower percentage (2.5%) in CDR-H3, excluding cysteines to prevent formation of random disulfide bonds. The combined naive library contained >10 10 unique clones.
To generate sABs that preferentially bind to the closed form of MBP (closed-specific sABs), we carried out selection with 10 µM maltose ( Fig. 1) . After four rounds of selection, we subjected the isolated colonies to competitive phage ELISA to estimate their affinity for MBP and specificity for the closed form ( Supplementary Fig. 1) . We sequenced the 48 sABs with the highest specificity for the closed form of MBP, leading to 17 unique clones. Of the 17 MBP closedspecific sABs, we expressed and purified for binding characterization 8 sABs, designated MCS1-MCS8, with the highest ELISA signal. In addition, we used a control sAB (MOS1), which was generated from a selection carried out without maltose, as an example of an open-specific sAB.
We determined the affinity of each of the sABs for MBP with and without maltose by surface plasmon resonance ( Table 1) . Representative sensograms for sAB binding to either form of MBP are in Supplementary Figure 2 . We analyzed the binding data and found that all sABs generated with maltose preferentially bind to the closed form of MBP with as much as a 2.3 kcal mol −1 difference in binding energy between the two forms. In contrast, MOS1, which was generated without maltose, has a high affinity (3 nM) for MBP without maltose ( Table 1) . With 1 µM maltose, the affinity was substantially decreased (30 nM), and we detected no binding with 1 mM maltose.
The effect of sABs on the affinity of MBP for maltose
We reasoned that sABs that selectively bind to the closed form of MBP can increase the affinity for maltose by shifting the equilibrium toward the bound form and vice versa. A convenient method for measuring the affinity of MBP for maltose is to monitor the liganddependent change in the emission of a single fluorophore attached at an introduced cysteine mutation 18,19 ( Fig. 2a) . We used the MBP S233C mutant conjugated to Alexa 488 to measure the effect of the sABs on the affinity of MBP for maltose. Using the fluorescence emission assay, we determined the affinity of MBP S233C for maltose with and without each of four closed-specific sABs (MCS1-MCS4). As we predicted, excess concentration of each of the sABs led to an increase in the affinity of MBP for maltose ( Fig. 2b) . MCS1 and MCS4, which have the highest preference for the closed form of MBP, induced the largest increases in the affinity of MBP for maltose ( Table 2) . We observed a similar increase in affinity for maltotriose (data not shown). We also determined the effect of the open-specific sAB MOS1 on maltose affinity. We used the change in intrinsic tryptophan fluorescence of MBP as a function of maltose binding to determine the affinity for maltose with or without MOS1 (Fig. 2c) . In contrast to the closed-specific sABs, MOS1 induced a large decrease in the affinity of a r t i c l e s MBP ( Fig. 2d ) for maltose with a ∆∆G resembling that of its preference for the open form of MBP ( Table 2) . Both closed-and open-specific sABs influenced the shape of the maltose-binding curves. Without sABs, the binding of maltose to MBP fits a single-ligand binding function. However, in the presence of sABs, we obtained best fits by adding the Hill coefficient to the equation. The closed-specific sABs MCS1 and MCS4 have Hill coefficients of 1.7 and 1.3, respectively, indicating positive cooperativity, whereas the Hill coefficient for MOS1 is 0.45, indicating negative cooperativity. We used the maltose-binding data with and without sABs to generate Scatchard plots ( Fig. 3) , which can be used to determine the allosteric contributions to ligand binding on the basis of the shape of the resulting curve 20 . Without sABs, maltose binding has a linear Scatchard plot, indicating no allostery ( Fig. 3a) . In contrast, both MCS1 and MCS4 lead to convex curves ( Fig. 3c,d) , a characteristic of positive allosteric effectors. In the case of MOS1, which binds preferentially to the open form, the curve is concave (Fig. 3b) , indicating that MOS1 acts as a negative allosteric effector 21 .
Structure of the sAB-MBP complex
To investigate the mechanism of the allosteric effect of the sABs, we crystallized the complex of MBP with sAB MCS2 in the presence of maltose ( Table 3 ). The maltose-bound MBP in complex with sAB MCS2 crystal contained one complex per asymmetric unit. Density was continuous for the heavy chain within residues 2-214, for the light chain within residues 2-213 and for MBP within residues 1-165 and 175-367. As we expected, the sAB primarily interacts with MBP through the CDR loops at the opposite side of the ligand-binding pocket and makes no contacts with the bound maltose ( Fig. 4) . The scaffold of the sAB resembles that of previously reported Fab fragments 15, 16 and the MBP structure closely overlaps with that of the maltose-bound structures of the protein 11, 12, 22 . The only substantial change is the shift of the loop comprising residues 166-185 in MBP, which in previously reported structures forms an extended β-strand loop that wraps around to the back face. In this structure, part of the loop (residues 166-174) appears disordered, and the other portion forms a more compact structure, which, in part, fills a void left by the C-terminal truncation of our MBP construct.
The majority of the interactions of the sAB with MBP are formed by residues from the heavy chain. The buried surface area is 864 Å 2 of the heavy chain compared with only 322 Å 2 of the light chain. A set of tryptophans and tyrosines in CDR-H1, CDR-H2 and CDR-H3 (Tyr33, Tyr53, Tyr56, Trp97, Trp98, Tyr99 and Trp100) form a wedge that has extensive hydrophobic and aromatic interactions with MBP ( Fig. 5a,b) . The residues from CDR-H3 (97-100) occupy a cleft between residues 90-98 and 314-327 of MBP that is present in the closed but not the open conformation. CDR-H2 (residues 52-56) occupies a surface along the helix between residues 90-98 of MBP and the following turn that in the open conformation is masked by the tip of the β-strand loop 166-185. CDR-L3 (residues 91-94) and 12 with our structure shows a clash between the CDR loops and the apo-MBP molecule ( Fig. 5c) , demonstrating the basis of the selectivity of the sAB for the maltose-bound form of MBP. The allosteric binding of the sAB to the closed conformation of MBP sheds light on the cooperative behavior of maltose binding in the presence of closed-specific sABs. In contrast to the MBP-MCS2 complex reported here, a previous structure of a sAB based on a monobody scaffold generated without maltose shows that the monobody interacts with an open form of MBP at the maltose-binding site 23 .
Functional rescue of an MBP mutant
Modulating protein-ligand interactions with an allosteric effector can restore the affinity of mutant proteins in which ligand-binding activity has been affected by the mutation. Using the crystal structure of the maltose-bound form of MBP, we generated a binding-pocket mutant with the W62F mutation. Although the mutation did not completely abolish maltose binding, it led to a ~2 kcal mol −1 decrease in binding energy (Fig. 6) . By adding a fivefold excess of MCS1 to the W62F mutant, we restored the affinity for maltose to near wild-type value, whereas addition of a fivefold excess of MCS4 led to a slightly higher affinity than that of the wild-type protein. The sABs did not affect the overall change in fluorescence between the apo and bound forms ( Fig. 6 ) but shifted the equilibrium to favor maltose binding and restore binding affinity.
Effect of sABs on maltose uptake in vivo
MBP is involved in the uptake of maltose and other sugars in the periplasm of Gram-negative bacteria. Recently, a crystal structure of the maltose transporter complex has clarified key elements in the mechanism of maltose transport and the role of MBP in this process 9 . Upon binding to maltose, the closed form of MBP is recognized by the MalF-MalG dimer, and an ATP hydrolysis step at the MalK protein allows the release of the sugar to the transporter by forcing the transition of MBP from the closed to the open form 24 . We reasoned that our closed-specific sABs can provide a growth advantage for bacteria at low concentrations of maltose by increasing the maltose affinity within the periplasm. We used Escherichia coli 55244 cells to periplasmically express sAB MCS1, MCS4 or a control sAB (sAB-27), which was previously generated to bind actin filaments 14 . The cells were grown in minimal media containing various concentrations of maltose as the sole carbon source and incubated with shaking at 30 °C. We determined growth curves by monitoring the A 595 values over 48 h. Cells expressing MCS1, MCS4 and sAB-27 showed similar growth rates under high concentrations of maltose. However, at low concentrations of maltose, the growth rates of cells expressing sAB-27 were substantially decreased, whereas the growth rates for cells expressing MCS1 or MCS4 were unaffected (Fig. 7) . These results indicate that cells expressing closed-specific sABs can thrive under low concentrations of maltose, presumably because sABs can shift the equilibrium of the open-to-closed transition of the intrinsic MBP N terminus Figure 4 Crystal structure of MBP-MCS2 complex. MBP (blue) is in the closed form, bound to one molecule of maltose (red). The sAB (heavy chain, green; light chain, yellow) interacts with MBP at the opposite side of the binding pocket, forming a wedge that favors the closed form. a r t i c l e s within the periplasm. This demonstrates the ability to dynamically change the affinity of a protein in vivo without introducing mutations in the protein itself but instead by introducing an external effector to modulate its activity.
DISCUSSION
Here we describe a rational approach to engineer a set of allosteric effectors that can modulate the affinity of a protein by generating conformational-selective sABs that favor either the ligand-free or ligandbound form of a protein. The sABs have nanomolar binding affinities for MBP and can discriminate between the two forms of the protein by as much as 2.3 kcal mol −1 . As a result, the sABs influence the affinity of MBP for its maltose ligand by shifting the equilibrium to either the open or the closed form of the protein. Because many proteins undergo conformational changes upon binding to a cognate ligand, the strategy presented here provides a general approach to engineering sABs that can manipulate the activity of a protein by dynamically influencing its conformation. Such conformational-selective sABs can serve as molecular switches for the regulation of protein function and are useful in studying protein-ligand interactions.
Our results indicate that the ability of the sABs to enhance the affinity of MBP for maltose is not related to the absolute affinity of the sAB for either conformational form of MBP but rather to the difference in affinity of the sABs for the two forms of the protein. In all four sABs tested (MCS1-MCS4), the degree of enhancement in maltose affinity (∆∆G maltose ) corresponds approximately to the difference in binding energy of each sAB (∆∆G closed -open ) between the open and the closed forms of MBP ( Table 2) . Additionally, maltose binding in the presence of the sABs shows cooperative behavior. Closed-specific sABs induce positive cooperativity, acting as classic heterotropic positive allosteric effectors 21 , as both the sAB and the maltose preferentially bind to the same form of MBP. On the other hand, the open-specific sAB MOS1 acts as a negative allosteric effector of maltose binding. Scatchard analysis of the binding behavior indicates that MOS1 does not simply act as a competitive antagonist (that is, competing with maltose for the same binding site), but instead MOS1 and maltose compete for two different conformations of the protein.
An important application of the rational design of allosteric effectors is rescuing binding function of an impaired mutant, which is a common feature of disease. We demonstrate here the ability of the closed-specific sABs to restore the affinity of the binding-pocket mutant MBP W62F. Notably, MCS4 has a greater effect on the affinity of the mutant for maltose than MCS1. We observed the opposite effect with wild-type MBP, in which MCS1 has a greater effect on affinity. This phenomenon is probably due to small changes in the overall structure that may result from the mutation within the binding pocket. Because of the large surface of interaction between the sABs and MBP, such small changes can influence the binding of each sAB differently. This observation suggests that the interactions of sABs with a target protein can be sensitive to subtle changes in structure or sequence. This high specificity of sAB-protein interactions can be used to probe minor fluctuations in the target protein conformation. Notably, the ability of sABs to restore the affinity of a mutant protein may be useful in rescuing the function of proteins in which mutations have decreased binding affinity, enzymatic activity or overall protein stability. sABs could be engineered as therapeutic reagents that stabilize the active form of a mutant protein, providing an alternative approach to gene therapy.
In addition to influencing the affinity of MBP for maltose in vitro, we sought to determine whether this set of sABs, when expressed in cells, could influence the effectiveness of maltose uptake in vivo. We showed that sABs, which recognize the closed form of MBP, produce a growth advantage for E. coli cells under low levels of maltose. The closed-specific sABs MCS1 and MCS4 are expressed in the periplasm, where each presumably interacts with the intrinsic MBP and shifts the equilibrium toward the closed form, making it a potent scavenger in a low-maltose environment. According to the current model for maltose transport, the closed form of MBP is recognized by the MalF-MalG transporter complex, and the energy from ATP hydrolysis by the MalK dimer is used to convert MBP into the open form, allowing maltose to pass through the transporter. Notably, there seems to be little thermodynamic penalty in the closed-to-open transition facilitating maltose transfer from the binding protein to the transporter owing to the presence of the sAB, suggesting that this is not the rate-determining step in the process.
The structure of the MCS2-MBP complex described here shows that sAB binding to MBP does not interfere with the interactions between MBP and the transporter. Although MCS2 does not enhance bacterial growth, limited epitope mapping studies (data not shown) suggest that sABs that enhance growth rates (such as MCS1 and MCS4) bind to a similar region on MBP. This suggests that engineering of sABs that influence nutrient uptake in bacteria could be used as a means to study bacterial transporters in vivo and may lead to a greater understanding of the underlying mechanisms by which bacteria respond to their environment. Notably, the results demonstrate that relatively simple selection strategies in vitro can translate into functional affinity modulators in vivo.
The data presented here demonstrate how library selection through phage display can be used to generate sABs with highly specific binding interactions. In contrast to traditional methods for generating monoclonal antibodies, this approach allows direct control over the conformational state of the target protein during the selection process. Indeed, monoclonal antibodies have been found to influence the interactions of proteins with their ligands. However, because it is extremely difficult to control the conformation of a target protein in the bloodstream of an immunized animal, such monoclonal antibodies have been either serendipitously discovered or identified through extensive screening efforts 6, 7 . The approach described here allows the production of highly specific binding reagents, as demonstrated by the observation that all closed-specific sABs chosen for characterization showed a preference for the closed form of MBP (see Table 1 ). A panel of sABs with a desired function can be generated by several rounds of selection; as a result, little to no screening is required to identify sABs with the desired function. Therefore, as a technology, conformational-selective phage display not only is cheaper and less time-and labor-intensive than monoclonal antibody generation but also allows rational engineering of allosteric effectors by applying selection instead of 'fishing' for a monoclonal antibody with the desired function. The resulting sABs act as modulators of protein affinity by shifting the equilibrium toward a specific structure of a protein in vitro and in vivo. This strategy is not limited to modulation of protein-ligand interactions. Similar selection strategies have led to the design of novel enhancers or inhibitors of enzymatic activity 25 . Furthermore, the ability to rescue the function of a mutant protein demonstrated here shows the importance of engineering conformational specificity. This approach may provide a general method for the rational design of protein-based therapeutics for many diseases in which mutations inhibit binding of a receptor to its natural ligand or the activity of a critical enzyme.
METhODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/nsmb/.
Accession codes. Protein Data Bank: Coordinates have been deposited with accession code 3PGF.
ONLINE METhODS
Phage display. MBP was expressed from the pHFT2_MBP plasmid (provided by A. Koide, University of Chicago, Chicago), which contains a His 10 tag, followed by a Flag tag at the N terminal of MBP lacking its periplasmic signal sequence and four amino acids at the C terminus. All mutants were constructed by Kunkel mutagenesis and verified by DNA sequencing. MBP variants were expressed in BL-21(DE3) cells grown in 1 l of LB medium supplemented with kanamycin and induced with 1 mM IPTG at an A 600 of 0.6 for 3 h at 37 °C. Cells were lysed by sonication, and the proteins were purified on a Ni-NTA column. MBP was biotinylated using sulfosuccinimidyl 2-(biotinamido)-ethyl-1,3-dithiopropionate (EZ-Link Sulfo-NHS-SS-Biotin, Thermo Scientific). The reaction contained 5 µM MBP in 50 mM MOPS, pH 7.0, and a 15-fold molar excess of biotinylation reagent for 45 min at 22 °C, followed by extensive dialysis into TBS (150 mM NaCl, 50 mM Tris-HCl, pH 7.5). Biotinylation was verified by mass spectrometry and a pulldown assay using streptavidin MagneSphere beads (Promega).
Biotinylated MBP (0.1 nmol) saturated with 10 µM maltose was adsorbed to a minimal quantity of streptavidin MagneSphere paramagnetic particles, and free streptavidin-binding sites were blocked with biotin to prevent nonspecific binding. After manual washing of the magnetic beads, 1 ml of phage library solution (10 12 -10 13 colony-forming units) was added and incubated at room temperature for 15 min, and then the phage solution was discarded and the beads were washed twice with TBST-BSA (TBS, 0.5% (w/v) Tween 20, 0.5% (v/v) BSA, 10 µM maltose). The captured phages on the magnetic beads were used directly to infect E. coli XL1-Blue cells (Stratagene) for phage amplification. The phage particles captured in the first round were cycled through additional rounds of binding and selection for immobilized MBP using an automated magnetic bead manipulator (KingFisher, Thermo Scientific). In the second round, phage solution was incubated with 100 µl of 50 nM biotinylated MBP for 15 min and then captured using streptavidin magnetic beads. After a total of five washing steps with 100 µl TBST-BSA with 10 µM maltose, the captured phages were eluted from the beads with 100 mM DTT in 20 mM Tris, pH 8.0, for 10 min and amplified in E. coli XL1-Blue. In the third round, the concentration of the biotinylated MBP was reduced to 10 nM. In the fourth round, the amplified phages were tested in two separate sorting experiments, one with 10 nM biotinylated MBP and the other with no MBP as a negative control. Recovered phages were titered, and the enrichment ratio was determined as the number of phage from the MBP-containing selection divided by the number of phage from the control selection. We obtained a substantial enrichment ratio after a total of three rounds in all experiments with an average >100.
Phages from the third round were produced from individual clones grown in a 96-well format. Culture supernatants were used directly in a single-point competitive phage ELISA with or without maltose to estimate the affinity and the conformational specificity of each clone. Escherichia coli XL1-Blue colonies (Stratagene) harboring phagemids were inoculated directly into 400 µl of 2YT broth supplemented with ampicillin (100 µg ml −1 ) and M13-KO7 helper phage (New England Biolabs); the cultures were grown overnight at 37 °C in a 96-well format. Culture supernatants containing sAB phage were diluted fivefold in PBS, 0.5% (w/v) BSA, 0.1% (v/v) Tween 20 (PBT buffer) either with or without MBP and maltose (20 nM MBP, 1 µM maltose). After 1 h incubation at room temperature, the mixtures were transferred to neutravidin-coated plates preloaded with 50 µl of 20 nM biotinylated MBP and were incubated for 15 min. The plates were washed with PBS, 0.05% (v/v) Tween 20, and were incubated for 30 min with horseradish peroxidase conjugated with antibody to M13(1:5,000 dilution in PBT buffer). The plates were washed, developed with 3,3′,5,5′-tetramethyl-benzidine and H 2 O 2 peroxidase substrate (Thermo Scientific), quenched with 1 M H 3 PO 4 and A 450 was determined. For each clone, the competition percentage was determined by dividing the A 450 signal in the presence of MBP by the A 450 without MBP. Clones that bound to MBP with 1 µM maltose but not without maltose were subjected to DNA sequencing. We obtained 17 unique clones from 48 colonies picked.
sAB expression and purification. The phagemid DNA from the selected sAB clones was purified and used as the template for Kunkel mutagenesis to introduce a stop codon between the sAB and the phage coat protein pIII, and then verified by DNA sequencing. sAB clones were used for large-scale protein expression in E. coli 55244 cells. The transformants were grown in 1 l of the CRAP media (27 mM (NH 4 ) 2 SO 4 , 14 mM KCl, 2.4 mM sodium citrate 5.4 g l −1 yeast extract, 5.4 g l −1 HyCase SF Casein, 0.11 M MOPS buffer, pH 7.3, 0.55% (w/v) glucose and 7 mM MgSO 4 ) supplemented with 100 µg ml −1 ampicillin. The cells were lysed using a microfluidizer in PBS supplemented with hen egg lysozyme (0.1 mg ml −1 ; Sigma) and DNase I (0.01 mg ml −1 ; Sigma). sABs were purified on rProteinA Sepharose 4 Fast Flow (GE Healthcare) using 20 mM sodium phosphate buffer supplemented with 0.5 M NaCl as a wash solution. After elution with 0.1 M acetic acid, the sABs were dialyzed into running buffer (10 mM HEPES, 150 mM NaCl, 50 µM EDTA, 0.005% (v/v) Tween 20, pH 7.4).
Surface plasmon resonance. Binding kinetics were determined using a BIAcore-2000 with sABs immobilized on a Ni-NTA chip (GE Healthcare). The purified protein samples were diluted at least 20-fold in the running buffer with and without 1 mM maltose. Serial dilutions of MBP with and without maltose were injected, and binding responses were corrected by subtraction of responses on a blank flow cell. The association and dissociation kinetics of MBP dilutions (60 µl each) were injected at 25 µl min −1 . For kinetic analysis, a 1:1 Langmuir model of global fittings of k on and k off was used. The K d values were determined from the ratios of k on and k off values.
Maltose-binding assays. Maltose binding was determined using either intrinsic tryptophan fluorescence or Alexa 488 fluorescence, both carried out on a FluoroMax-3 fluoremeter. MBP S233C was labeled with a tenfold molar excess of Alexa 488 maleimide (Invitrogen) in 20 mM MOPS, 100 mM NaCl, pH 6.9, (labeling buffer) at room temperature for 1 h or overnight at 4 °C, followed by gel filtration chromatography using an Econopac 10-DG column (Bio-Rad) to remove excess fluorophore. For intrinsic tryptophan fluorescence measurements, the protein was excited at 270 nm, and for Alexa 488 fluorescence measurements, the protein was excited at 488 nm. Maltose was directly titrated into 3 ml of labeling buffer containing 1-10 nM MBP or MBP S233C-Alexa 488 with or without fivefold excess of sAB. Changes at the emission maximum were monitored as a function of maltose concentration. Binding curves were fitted using Kaleidagraph.
X-ray crystallography. His-tagged MBP was dialyzed into TBS with 1 mM maltose and 1 mM DTT. The MBP-MCS2 complex was prepared by combining a 1.5 molar excess of MBP with MCS2 and purified using a Superdex 200 column (GE Healthcare) equilibrated with 20 mM HEPES, pH 7.5, 100 mM NaCl, 1 mM maltose, 1 mM DTT. The complex was crystallized by the hanging-drop method over 1 ml well solution containing 19% (w/v) PEG 3400 and 8% (w/v)Tacimate, pH 6.0 (Hampton Research). Crystals formed after 1 month at 19 °C. Crystals were cryoprotected with a solution of 20% (w/v) PEG 3400, 10% (w/v) Tacsimate, pH 6.0, and 23% (v/v) glycerol, and were flash frozen. Data were collected at 21-ID-D LS-CAT at the Advanced Photon Source and processed with HKL2000 (ref. 26) . Initial phases were determined using Phaser 27 in CCP4 by molecular replacement 28 with a closed MBP structure 22 and the Fab scaffold 16 . Manual addition of CDR loops was done in Coot 29 , followed by atomic position refinement using alternating rounds of manual rebuilding in Coot and restrained refinement in Refmac5 (ref. 30) . Translation/libration/screw (TLS) domains were determined using the TLSMD server and TLS parameters were also refined in Refmac5 (refs. [31] [32] [33] . Waters were added using Arp/Warp 34 . Figures were created in PyMOL 35 .
In vivo assay. Escherichia coli 55244 cells were transformed with plasmids coding for MCS1, MCS4 or sAB-27. Overnight cultures in LB (1 ml) were used to inoculate cultures in a 96-deep-well plate containing 1.2 ml of CRAP media supplemented with ampicillin and grown overnight. The cultures were diluted into another deep-well plate containing 1.2 ml minimal media (2 g (NH 4 ) 2 SO 4 , 0.5 mg FeSO 4 ·7H 2 O, 75 mg KCl, 125 mg thiamine, 50 mg MgCl 2 and 7.5 g l −1 triethanolamine) in each well with 0.02%, 0.04%, 0.2%, 0.4% maltose or 0.4% glucose (all w/v). The growth of the cultures was monitored by measuring the A 595 (TECAN plate reader) of 100 µl aliquots removed from each well at various time points over 48 h.
